

Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis

Simona Soverini,¹ Antonella Vitale,² Angela Poerio,¹ Alessandra Gnani,¹ Sabrina Colarossi,¹ Ilaria Iacobucci,¹ Giuseppe Cimino,² Loredana Elia,² Annalisa Lonetti,¹ Marco Vignetti,² Stefania Paolini,¹ Giovanna Meloni,² Valeria di Maio,² Cristina Papayannidis,¹ Marilina Amabile,¹ Anna Guarini,² Michele Bacarani,¹ Giovanni Martinelli,¹ and Robin Foà²

¹Department of Hematology and Oncological Sciences “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy, and ²Department of Hematology and Cellular Biotechnologies, “Sapienza” University of Rome, Rome, Italy

Citation: Soverini S, Vitale A, Poerio A, Gnani A, Colarossi S, Iacobucci I, Cimino G, Elia L, Lonetti A, Vignetti M, Paolini S, Meloni G, di Maio V, Papayannidis C, Amabile M, Guarini A, Bacarani M, Martinelli G, and Foà R. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. *Haematologica* 2011;96(4):552-557. doi:10.3324/haematol.2010.034173

Online Supplementary Table S1. Cytogenetic data at diagnosis and at the time of relapse.

N	Sex	Age	Karyotype at diagnosis	Mutations at diagnosis (cloning and seq)	Mutation at relapse (D-HPLC and direct seq)	Karyotype at relapse
1	M	54	46,XY,del(9)(p11),t(9;22)(q34;q11),der(12)[20]	L266P; A337A	T315I	46,XY,del(9)(p11),t(9;22)(q34;q11),t(12;14)(q11;p11),der(22)[20]
2	M	56	46,XY,del(9)(p13p22),t(9;22)(q34;q11)[20]	V289A; V335V; K378E; L411P	T315I	46,XY,del(9)(p13p22),t(9;22)(q34;q11)[14] / 46,idem,t(2;9)(q?q?);t(2;19)(q?p?) [3]
3	M	56	N.E.	L298P; R307Q; W405C	WT	N.E.
4	F	49	46,XX,t(9;22)(q34;q11) [20]	E275E; E281K; T319A; N336D	WT	46,XX,t(9;22)(q34;q11)[10]
5	F	74	46,XX,t(9;22)(q34;q11) [20]	G250R; I293T; V304I; D363D; R367stop; K378E	T315I	46,XX,t(9;22)(q34;q11)[20]
6	F	58	N.E.	K245R; L327L	E255K	N.E.
7	F	61	46,XX,t(9;22)(q34;q11)[10]	I293T; V304I; T315I; C346stop; W405C; P439L	T315I	N.D.
8	F	30	46,XX,t(9;22)(q34;q11)[20]	Y264C; T315I; A344T; L451L	T315I	N.E.
9	F	58	N.D.	Q252stop; L384P; T392I; A407A; N479S	--	--
10	F	34	46,XX,t(9;22)(q34;q11) [20]	K245R; A288T; R460R	--	--
11	M	52	46,XY,t(9;22)(q34;q11)[14] / 45,XY,-7,t(9;22)(q34;q11)[3] / 44,XY,-7,t(9;22)(q34;q11),-11[3]	G254E; Y326Y; E334E; A487V	--	--
12	F	73	46,XX,t(9;22)(q34;q11)[5] / 46,XX[2]	E352K; A380A; T389T; Q477stop	--	--
13	M	72	N.E.	G249S; Y253Y; Y257H; E292G; F317L; Y342Y; Y353Y; H396P	--	--
14	F	36	46,XX,t(9;22)(q34;q11)[20]	E352G; A366A	--	--
15	M	50	46,XY,t(9;22)(q34;q11)[10]	E286E; I360T; I403T; N479S	--	--

The number of evaluable metaphases is indicated in parentheses. M, male; F, female; seq, sequencing; D-HPLC, denaturing high performance liquid chromatography; WT, wild-type; N.E.: not evaluable (no metaphases could be obtained); N.D.: not done (because of punctio sicca or failure to send the bone marrow sample to the central reference laboratory).